# Filing Detail

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001193125-25-326263
Filing Date
2025-12-19
Accepted
2025-12-19 12:32:00
Documents
5

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | primary_doc.html | SCHEDULE 13D |
1 |  | primary_doc.xml | SCHEDULE 13D | 19523
2 | EX-99.A | ck0000000000-ex99_a.pdf | EX-99.A | 131007
3 | EX-99.F | ck0000000000-ex99_f.pdf | EX-99.F | 990193
4 | EX-99.G | ck0000000000-ex99_g.pdf | EX-99.G | 892171
5 | EX-99.H | ck0000000000-ex99_h.pdf | EX-99.H | 1003739
| Complete submission text file | 0001193125-25-326263.txt |  | 4177822

Mailing Address TOLDBODGADE 33 1253 COPENHAGEN K G7 00000
Business Address TOLDBODGADE 33 1253 COPENHAGEN K G7 00000
GENMAB A/S (Filed by) CIK: 0001434265 (see all company filings)

EIN.: 000000000
Type: SCHEDULE 13D
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address YALELAAN 62 3584 CM UTRECHT DE
Business Address YALELAAN 62 3584 CM UTRECHT DE 31 030 253 8800
Merus N.V. (Subject) CIK: 0001651311 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-89510 | Film No.: 251586509
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)